To investigate the survival benefit of first-line therapy for patients with EGFR-sensitive
mutation-positive advanced non-squamous non-small cell lung cancer treated with S-1plus
gefitinib versus gefitinib monotherapy
This is a randomized, controlled, open-plan, prospective clinical study. According to the
available evidence, we selected patients with locally advanced or metastatic non-squamous
non-small cell lung cancer with stage -C- confirmed by cytology or histology and positive
EGFR-sensitive mutation, then patients accept first-line treatment with S-1 plus gefitinib or
gefitinib. This study will collect FFS during treatment until the patient dies and will
follow the survival of the subject after the disease progresses.
EGFR-sensitive Mutation-positive Advanced Non-squamous Non-small Cell Lung Cancer Treated With S-1plus Gefitinib Versus Gefitinib Monotherapy,
Advanced NSCLC With EGFR Mutation
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.